ecancermedicalscience

Review

Dihydropyrimidine dehydrogenase (DPD) polymorphisms knocking on the door

17 Jan 2022
Mauro Daniel Spina Donadio, Dirce Maria Carraro, Giovana Tardin Torrezan, Celso Abdon Lopes de Mello

Identifying polymorphisms in the dihydropyrimidine dehydrogenase (DPYD) genes is gaining importance as predictors of fluoropyrimidine-associated toxicity. The recommendation of dose adjustment for chemotherapy guided by the presence of polymorphisms of the DPYD gene can potentially improve treatment safety for a large number of patients, saving lives, avoiding complications and reducing health care costs. This article discusses how personalisation of fluoropyrimidine treatment based on the identification of DPYD variants can mitigate toxicities and be cost effective.

Related Articles

Beatrice P Mushi, Summaiya Haddadi, Alita Mrema, Jerry Ndumbalo, Nanzoke Mvungi, Msiba Selekwa, Julius Mwaiselage, Larry Akoko, Yona Ringo, Rohan Luhar, Rebecca DeBoer, Katherine Van Loon, Elia Mmbaga, Geoffrey C Buckle
Ally H Mwanga, Erick M Mbuguje, Jeanine Justiniano, Balowa Musa, Nashivai Kivuyo, Daniel W Kitua, Eva Uiso, Andrew Swallow, Edith Kimambo, Azza Naif, Deogratius B Mwanakulya, Swaleh Pazi, Advera Ngaiza, Seif Wibonela, Behnam Shaygi, Cameron E Gaskill
Lingaraj Nayak, Gaurav Salunke, Trupti Gilada, Sukhada Savarkar, Bindiya Salunke, Sanjay Biswas, Vanita Noronha, Atul Kulkarni, Manju Sengar, Akshay Baheti, Pradnya Samant, Anant Gokarn, Anuradha Mehta, Chetan Dhamne, Keerthna Batyala
Sasongko Hadi Priyono, Winardi Budiwinata, Budianto Tedjowitono, Effendy, Muhamad Daffa Ibnurasy Pratama
Ghazal Tansir, Akhil Santhosh, Akash Kumar, Hemavathi Baskarane, Mohit Kumar Divakar, Vishakha Hooda, Arundhati J R Dev, Chandra Prakash Prasad, Ishaan Gupta, Saran Kumar, Pranay Tanwar, Atul Sharma, Sameer Bakhshi, Atul Batra